Gossamer Bio (GOSS) Earnings Analysis
Gossamer Bio (GOSS) has no confirmed upcoming earnings date. Last quarter (2026-05-18) it missed with EPS -0.2 USD vs -0.17 USD est (-17.6%). It has beaten estimates in 3/6 recent quarters (50%). Trailing P/E -0.18.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does GOSS next report earnings?
No confirmed upcoming earnings date is currently scheduled for GOSS. This page updates as the calendar is published.
GOSS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-18 | -0.2 USD | -0.17 USD | -17.6% | Miss |
| 2026-03-17 | -0.21 USD | -0.2 USD | -5% | Miss |
| 2025-05-15 | -0.16 USD | -0.18 USD | +11.1% | Beat |
| 2025-03-13 | -0.15 USD | -0.17 USD | +11.8% | Beat |
| 2024-11-07 | -0.14 USD | -0.18 USD | +22.2% | Beat |
| 2024-08-12 | 0.22 USD | 0.23 USD | -4.3% | Miss |
Beat rate: 3/6 (50%) over reported quarters with consensus data.
GOSS valuation and analyst view
| Trailing P/E | -0.18 |
|---|---|
| Trailing EPS | -0.77047 USD |
| Price / book | -0.21 |
| Dividend yield | 0.00% |
| Market cap | 0.03B |
| Analyst consensus | Buy (9 buy / 6 hold / 2 sell) |
| Avg price target | 4.06 USD |
Related research pages
Frequently asked questions
When is Gossamer Bio (GOSS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for GOSS. This page updates as the calendar is published.
Did GOSS beat earnings last quarter?
In its 2026-05-18 report, GOSS posted EPS of -0.2 USD versus a -0.17 USD estimate — a miss of 17.6%.
What is GOSS's earnings track record?
Over the last 6 reported quarters with consensus data, GOSS beat estimates 3 times (50%).
What is GOSS's current P/E ratio and EPS?
GOSS trades at a trailing P/E of -0.18 on trailing EPS of -0.7704707908132082 USD.
What do analysts rate GOSS?
Analyst consensus is "Buy" across 17 ratings (0 strong buy, 9 buy, 6 hold, 2 sell, 0 strong sell). Average 12-month price target: 4.06 USD.